Clinical Trial Articles

Articles
Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial
Sayed A, Brophy JM
Journal:
Int J Cardiol

First published: April 19, 2024 DOI: 10.1016/j.ijcard.2024.132074
View
- Share
Articles
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
View
- Share
Articles
Oral PCSK9 Inhibitors
Agarwala A, Asim R, Ballantyne CM
Journal:
Curr Atheroscler Rep

First published: March 13, 2024 DOI: 10.1007/s11883-024-01199-2
View
- Share
Articles
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
Xie S, Galimberti F, Olmastroni E, et al.
Journal:
Cardiovasc Res

First published: February 19, 2024 DOI: 10.1093/cvr/cvae034
View
- Share
Articles
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
Sayah N, Bhatt DL, Miller M, et al.
Journal:
Eur Heart J

First published: January 22, 2024 DOI: 10.1093/eurheartj/ehad889
View
- Share
Articles
Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
Nicholls SJ, Nelson AJ, Lincoff AM, et al.
Journal:
JAMA Cardiol

First published: January 17, 2024 DOI: 10.1001/jamacardio.2023.5155
View
- Share
Articles
Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States
Weintraub WS, Bhatt DL, Zhang Z, et al.
Journal:
J Am Heart Assoc

First published: December 29, 2023 DOI: 10.1161/JAHA.123.032413
View
- Share
Articles
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Ray KK, Nicholls SJ, Li N, et al.
Journal:
Lancet Diabetes Endocrinol

First published: December 4, 2023 DOI: 10.1016/S2213-8587(23)00316-9
View
- Share
Articles
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial
Nissen SE, Linnebjerg H, Shen X, et al.
Journal:
JAMA

First published: November 12, 2023 DOI: 10.1001/jama.2023.21835
View
- Share
Articles
Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial
Lee B, Hong SJ, Rha SW, et al.
Journal:
Atherosclerosis

First published: November 10, 2023 DOI: 10.1016/j.atherosclerosis.2023.117373
View
- Share
Articles
Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
Tokgözoğlu L, Pirillo A, Catapano AL
Journal:
Eur Heart J

First published: November 4, 2023 DOI: 10.1093/eurheartj/ehad485
View
- Share
Articles
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial
Patel S, Bonaca M, Morrow D, et al.
Journal:
JACC Adv

First published: November 1, 2023 DOI: 10.1016/j.jacadv.2023.100675
View
- Share

1 2

Clinical Trial Articles

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Articles

Oral PCSK9 Inhibitors

Agarwala A, Asim R, Ballantyne CM

Articles

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Articles

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Sayah N, Bhatt DL, Miller M, et al.

Articles

Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial

Nicholls SJ, Nelson AJ, Lincoff AM, et al.

Articles

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States

Weintraub WS, Bhatt DL, Zhang Z, et al.

Articles

Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial

Ray KK, Nicholls SJ, Li N, et al.

Articles

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

Nissen SE, Linnebjerg H, Shen X, et al.

Articles

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Lee B, Hong SJ, Rha SW, et al.

Articles

Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Tokgözoğlu L, Pirillo A, Catapano AL

Articles

Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial

Patel S, Bonaca M, Morrow D, et al.

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Share

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Share

Articles

Oral PCSK9 Inhibitors

Agarwala A, Asim R, Ballantyne CM

Share

Articles

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Share

Articles

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Sayah N, Bhatt DL, Miller M, et al.

Share

Articles

Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial

Nicholls SJ, Nelson AJ, Lincoff AM, et al.

Share

Articles

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States

Weintraub WS, Bhatt DL, Zhang Z, et al.

Share

Articles

Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial

Ray KK, Nicholls SJ, Li N, et al.

Share

Articles

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

Nissen SE, Linnebjerg H, Shen X, et al.

Share

Articles

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Lee B, Hong SJ, Rha SW, et al.

Share

Articles

Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Tokgözoğlu L, Pirillo A, Catapano AL

Share

Articles

Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial

Patel S, Bonaca M, Morrow D, et al.

Share